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Abstract
NK cells have therapeutic potential for a wide variety of human malignancies. However, because NK cells expand poorly in
vitro, have limited life spans in vivo, and represent a small fraction of peripheral white blood cells, obtaining sufficient cell
numbers is the major obstacle for NK-cell immunotherapy. Genetically-engineered artificial antigen-presenting cells (aAPCs)
expressing membrane-bound IL-15 (mbIL15) have been used to propagate clinical-grade NK cells for human trials of
adoptive immunotherapy, but ex vivo proliferation has been limited by telomere shortening. We developed K562-based
aAPCs with membrane-bound IL-21 (mbIL21) and assessed their ability to support human NK-cell proliferation. In contrast
to mbIL15, mbIL21-expressing aAPCs promoted log-phase NK cell expansion without evidence of senescence for up to 6
weeks of culture. By day 21, parallel expansion of NK cells from 22 donors demonstrated a mean 47,967-fold expansion
(median 31,747) when co-cultured with aAPCs expressing mbIL21 compared to 825-fold expansion (median 325) with
mbIL15. Despite the significant increase in proliferation, mbIL21-expanded NK cells also showed a significant increase in
telomere length compared to freshly obtained NK cells, suggesting a possible mechanism for their sustained proliferation.
NK cells expanded with mbIL21 were similar in phenotype and cytotoxicity to those expanded with mbIL15, with retained
donor KIR repertoires and high expression of NCRs, CD16, and NKG2D, but had superior cytokine secretion. The mbIL21-
expanded NK cells showed increased transcription of the activating receptor CD160, but otherwise had remarkably similar
mRNA expression profiles of the 96 genes assessed. mbIL21-expanded NK cells had significant cytotoxicity against all tumor
cell lines tested, retained responsiveness to inhibitory KIR ligands, and demonstrated enhanced killing via antibody-
dependent cell cytotoxicity. Thus, aAPCs expressing mbIL21 promote improved proliferation of human NK cells with longer
telomeres and less senescence, supporting their clinical use in propagating NK cells for adoptive immunotherapy.
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Introduction
NK cells are potent effectors of the innate immune system [1]
with cytotoxic and immunoregulatory function [2,3]. Human NK
cells are typically characterized as lymphocytes (CD2
pos) expressing
CD56 or CD16 and lacking CD3 expression [4], and make up from
1–32.6% of peripheral blood lymphocytes in normal subjects [5].
Recently, NKp46 has been suggested as a unifying marker of NK
cells across species [6]. Unlike T-cells, NK cells recognize targets in
a major histocompatibility complex (MHC)-unrestricted manner.
NKcellsdisplay a varietyofactivating receptors,includingNKG2D
and the natural cytotoxicity receptors NKp30, NKp44, NKp46,
whose activation signals compete with inhibitory signals provided
primarily by killer immunoglobulin receptors (KIR) and CD94/
NKG2A. NK cells play an important role in initiating responses to
infection, including infections of importance in the peri-transplant
setting such as cytomegalovirus (CMV), herpes simplex virus
(HSV), respiratory syncitial virus (RSV), and influenza. Donor
KIR-mismatched NK cells can suppress recipient derived lympho-
cytes, reducing the risk of rejection, and react against recipient
dendriticcells[7],therebyreducingtheallostimulousforGvHD [8].
With antiviral, anti-GvH, and anti-cancer potential, adoptive
immunotherapy with natural killer (NK) cells has emerged as
promising anti-cancer treatment. NK cells have therapeutic
potential for a wide variety of human malignancies, including
sarcomas [9,10], myeloma [11], carcinomas [12,13,14,15], lym-
phomas [16], and leukemias [14,17,18]. Until recently, the clinical
efficacy and effective application of NK cell immunotherapy has
been limited by the inability to obtain sufficient cell numbers for
adoptive transfer, as these cells represent a small fraction of
peripheral white blood cells, expand poorly ex vivo, and have limited
life spans in vivo. The ability to harvest large numbers of peripheral
blood lymphocytes through leukapheresis, deplete alloreactive T
cells,andactivatethe remainingNKcellswithIL-2 hasenabled NK
cell adoptiveimmunotherapy,butthisprocessisexpensive,invasive,
and remains limited in cell dose to a single infusion of typically less
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7 NK cells/kg [19]. Using this approach, Miller et al [14]
demonstrated that infusion of haploidentical NK cells after
chemotherapy could induce remission in poor-prognosis AML
patients, and remission was associated with KIR mismatch. In a
similar study, Rubnitz et al [18] reported the safety of KIR-
mismatched NK cell infusion as post-remission consolidation
therapy for children with AML, with no relapses reported in the
10 patients treated. A similar approach has been used for adoptive
transfer of NK cells in patients with refractory lymphoma [16] and
multiple myeloma [20]. GvHD was not reported in any of these
studies.
Identifying the optimal signal for propagation of NK cells in vitro
has been problematic due in part to the large number of activating
and inhibitory receptors, cooperative receptor pairs, and overlap-
ping signaling pathways involved in maturation, activation, and
proliferation. Expansion of donor NK cells has been reported with
various combinations of cytokines [17,21,22,23,24,25,26,27,28],
cytokine fusion proteins [29,30], cytokines and OKT3 [11,12,31,
32,33,34], cytokines and stromal support [35], antibody-coated
beads [36], bisphosphonate-capped dendrimers [37], methyl-b-
cyclodextrin [38], or feeder cells derived from EBV-lymphoblas-
toid cell lines [39,40,41,42,43] or K562 [44,45,46,47]. K562-
based aAPCs transduced with 4-1BBL (CD137L) and membrane-
bound IL-15 (mbIL15) [45] promoted a mean NK-cell expansion
of 277-fold in 21 days, but continued proliferation was limited by
senescence attributed to telomere shortening. K562 expressing
CD137L, MICA, and soluble IL-15 yielded a mean NK cell
expansion of 550-fold in 24 days [46]. The highest doses of NK
cells yet reported to be infused into patients were derived by
expanding autologous CD3-depleted pheresis products for three
weeks with IL-2, OKT3, and irradiated PBMC feeder cells [48].
With the development of methods to expand primary human
NK cells in vitro, there is now renewed interest in NK cell
immunotherapy [13,22,26,41,45].
Common c-chain cytokines, of which IL-2, IL-15 and IL-21 are
members, are important in NK cell activation, maturation, and
proliferation. IL-15 has a well-recognized role in maturation,
survival, and homeostatic expansion of NK cells. The discovery of
IL-21 was linked to its role in proliferation and maturation of NK
cells [49], but subsequent studies have been widely disparate,
identifying it as both activating and suppressive [50,51,52].
Although soluble IL-21 alone does not induce significant
proliferation of mature murine NK cells and IL-21R knockout
mice have normal NK cell numbers [50], IL-21 synergizes with
IL-2, IL-15, and Flt-3L in the generation of NK cells from bone
marrow [49] and cord blood [49,53,54,55,56]. IL-21 may activate
NK cell lytic activity through upregulation of costimulatory
receptors, perforin, and granzyme [57]. To exploit this potential
of these cytokines, we developed membrane-bound chimeras of
IL-21 (mbIL21) and IL-15 (mbIL15), and investigated NK cell
expansion, phenotype, and function in response to K562 aAPCs
genetically modified with mbIL21 and/or mbIL15.
Materials and Methods
Ethics Statement
All work with human samples was performed under protocols
approved by the Institutional Review Board of MDACC and/or
BCM. Written informed consent to participation in an approved
protocol was obtained from all participants (or next of kin/legal
guardian) prior to collection of samples, with the exception of such
cases in which the requirement for consent was waived by the IRB
(e.g., anonymized buffy coats from the local blood bank or
commercially available human cell lines). Human NK cells were
purified or expanded from anonymized blood bank buffy coats
obtained under this IRB-approved protocol. Human tumor xeno-
grafts were established according to protocol 05-07-04832 approved
by the Institutional Animal Care and Use Committee of MDACC.
Cells and cell lines
Anonymized normal human donor buffy coats were obtained
from the Gulf Coast Regional Blood Center (Houston, TX).
721.221 cell lines, including those genetically-modified to
express selected KIR ligands, were obtained as previously
described [58]. The parental K562 cell line was obtained from
the American Type Culture Collection (ATCC). K562 aAPCs
(Table 1) [59] were produced by retroviral transduction with
CD64 (FccRI), CD86 (B7-2), CD137L (4-1BBL), and truncated
CD19 to create the core aAPC designated Clone 9, or with the
same four core transgenes and mbIL15 to create the aAPC
designated Clone 4, as described previously [60]. Clone D2 and
Clone 9.mbIL21 were created by transducing Clone 4 and Clone
9, respectively, with a Sleeping Beauty transposon expressing mbIL21
as described previously [61]. Clone 27 was created by transducing
Clone 9 with a Sleeping Beauty transposon expressing IL-15 fused to
IL-15Ra with a linker. aAPC clones were selected for high
transgene expression after single-cell cloning (Clone 9.mbiL21
shown in Figure 1A), except aAPC Clone D2 which was selected
for high transgene expression by high-speed flow sorting.
AML10 human leukemic myeloblasts were obtained from the
peripheral blood of a newly-diagnosed pediatric patient after
written consent was obtained under an IRB-approved collection
and banking protocol. AML10 cells were expanded by serial
passage in NOD.Cg-Rag1
tm1MomPrf1
tm1Sdz/SzJ mice (Jackson Lab-
oratories) [62], and verified .98% human CD33
pos after recovery.
Raji and ARH-77 were obtained from ATCC. CHP134 and SK-
N-BE(2) were obtained from the COG Cell Culture and
Xenograft Repository. U937 was a gift from T. Horton of Baylor
College of Medicine, Houston TX (BCM). SAOS-2, HCT15, and
SK-MEL-37 were obtained from E. Kleinerman, D. Hughes, and
L. Radvanyi, respectively, of the University of Texas MD
Anderson Cancer Center (MDACC).
Allcell lineswerevalidated bySTR DNAfingerprinting usingthe
AmpF,STR Identifiler kit according to manufacturer instructions
(Applied Biosystems cat 4322288). The STR profiles were
compared to fingerprint data on the ATCC fingerprint database
(ATCC.org), the Cell Line Integrated Molecular Authentication
database (CLIMA) version 0.1.200808 (bioinformatics.istge.it/
clima/), the COG Cell Line and Xenograft STR Database
(strdb.cogcell.com/), and the MD Anderson fingerprint database.
The STR profiles were last performed on October 15, 2010 and
either matched to their known DNA fingerprints, or were unique
(AML10 and AML13).
Table 1. Artificial APCs used in this study.
aAPC name Cytokine transgene
Clone 9 None
Clone 4 Membrane-bound IL-15 mutein (mbIL15)
Clone 27 IL-15 fused to IL-15Ra with linker
Clone 9.mbIL21 Membrane-bound IL-21 mutein (mbIL21)
Clone D2 mbIL15 and mbIL21
All aAPCs include the transgenes for tCD19, CD64, CD86, and CD137L.
doi:10.1371/journal.pone.0030264.t001
mbIL21 Expansion of NK Cells
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Murine anti-human NKp30, NKp44, NKp46, CD16, CD56,
NKG2D, isotype control mAb, and the mouse IgG2a anti-
disialoganglioside GD2 (clone 14.G2a) were obtained from BD
Biosciences (Bedford, MA). Murine anti-human KIR2DL2/3 was
obtained from Miltenyi(Auburn, CA).Murine anti-human KIR2DL1
and KIR3DL1 were obtained from R&D Systems (Minneapolis,
MN). The humanized IgG1 anti-human CD20 (rituximab, Genen-
tech) was purchased through the institutional pharmacy.
NK cell purification by negative selection
NK cells wereenriched from buffy coats withRosetteSep Human
NK Cell Enrichment Cocktail (StemCell Technologies, Inc.,
Vancouver, BC, Canada), using 10 mL per 1 mL of buffy coat.
When further purification was needed to achieve NK cell purity to
$95% (as assessed by flow cytometry as CD3
negCD56
pos), or for
depletion of T cells during NK cell expansion, the method of
Warren et al. was used [63], in which 3rd party RBCs were added to
enhance agglutination and depletion of unwanted cells.
Ex vivo expansion of human NK cells
NK cells were cultured in NK cell media consisting of RPMI
1640 (Cellgro/Mediatech, Manassas, VA) supplemented with
50 IU/ml recombinant human IL-2 (Proleukin, Novartis Vaccines
and Diagnostics, Inc), 10% Fetal Bovine Serum (Invitrogen,
Carlsbad, CA), L-glutamine (Gibco/Invitrogen, Carlsbad, CA),
and penicillin/streptomycin (Cellgro/Mediatech, Manassas, VA).
NK cells were expanded from PBMC as previously described
(Figure 2) [64]. Briefly, peripheral blood mononuclear cells
(PBMC) were first isolated from buffy coats using Ficoll-Paque
Plus (GE HealthCare, Piscataway, NJ). PBMC were co-cultured in
T-75 flasks (Corning, Corning, NY) with irradiated (100 cGy)
K562 aAPCs at a ratio of 1:2 (PBMC:aAPC) in NK cell media at
2610
5 PBMC/mL. Cultures were refreshed with half-volume
media changes every two to three days, and re-stimulated with
aAPCs at ratio of 1:1 every seven days. When necessary, a portion
of the expanding cells was carried forward for subsequent
stimulations, and the remaining cells cryopreserved. NK cell
expansion was calculated from the resulting cultures as if all cells
Figure 1. Surface expression of CD15 and transgene receptors on Clone 9.mbIL21 aAPC, and stability of expression of relevant
receptors. After limiting-dilution cloning, cloned aAPCs were assessed for expression of transgenes, A. Since CD15 expression was variable among
the clones and is felt to play a role in NK cell activation, its expression was also assessed. After selection of a clone with expression of all surface
proteins, the clone was maintained in culture for 6 months, with periodic re-evaluation of CD137L and mbIL21 expression, B.
doi:10.1371/journal.pone.0030264.g001
Figure 2. Schema for NK cell manufacturing with aAPCs. Artificial antigen-presenting cells (aAPCs) were produced by genetic modification of
K562 to express costimulatory molecules and membrane-bound cytokines. To expand NK cells ex vivo, unfractionated PBMC are stimulated weekly
with irradiated PBMC, inducing rapid proliferation of NK cells and in some cases non-specific expansion of T cells. Contaminating T cells may be
depleted, and the remaining purified NK cells may be stimulated weekly by the aAPCs as needed to obtain sufficient numbers. Expanded NK cells
may be used directly or cryopreserved for future use.
doi:10.1371/journal.pone.0030264.g002
mbIL21 Expansion of NK Cells
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Figure 3B and D, expansion cultures were initiated from purified
NK cells instead of unfractionated PBMC, or T cells were depleted
from the expansion culture prior to the 3rd stimulation at day 14.
Flow cytometry
For direct surface staining, cells were incubated with indicated
antibodies for 30 min at 4uC, washed, and resuspended in staining
buffer. Data were acquired using a FACSCalibur cytometer (BD
Biosciences) and analyzed using FlowJo software (Tree Star, Inc.,
Ashland, OR). The expanding cell subpopulations (T/NKT
(CD3
pos) and NK (CD3
neg and CD16-or-56
pos)) and NK cell
phenotypes were determined weekly during expansion.
Cytotoxicity assay
NK cell cytotoxicity was determined using the calcein release
assay, a fluorometric assay comparable to the chromium release
assay in determining NK cell cytotoxicity [65,66], as described
[64]. Target cells were labeled with 0.5–5 mg/mL (titrated for each
target cell line) of calcein-AM (Sigma-Aldrich) for 1 h at 37 uC
with occasional shaking. Cells were co-cultured at the indicated
effector-to-target (E:T) ratios and incubated at 37 uC for 4 h. After
incubation, 100 mL of the supernatant was harvested and trans-
ferred to a new plate. Absorbance at 570 nm was determined
using a SpectraMax Plus
384 spectrophotometer. The percent lysis
was calculated according to the formula [(experimental release2
spontaneous release)/(maximum release2spontaneous release)]6
100. For ADCC experiments, antibodies were added to the lysis
culture at 1 mg/mL. Video fluorescent microscopy of NK cells
lysing calcein-loaded neuroblastoma targets was performed at a
5:1 E:T ratio using the Nikon BioStation, with images obtained
every 4 minutes.
Telomere length analysis
NK cells were purified from buffy coat by the RosetteSep
method, and an aliquot of the NK cells viably frozen. The
Figure 3. NK cell expansion and purity after repeated weekly stimulation with aAPCs expressing membrane-bound cytokines. A,
Mean expansion of CD3
neg/CD16-or-56
pos NK cells from 22 donors expanded for 21 days using aAPCs bearing mbIL15 or mbIL21. NK cells from five
donors were also expanded with aAPCs expressing both mbIL15 and mbIL21. B, Mean expansion of NK cells from 4 donors expanded for 42 days
using aAPCs bearing mbIL15 or mbIL21. C, Percent of CD3
pos T/NKT cells and CD3
neg/CD16-or-56
pos NK cells in the starting PBMC product (day 0) and
at the end of 21 days of expansion on Clone 9.mbIL21 from 20 donors. D, Mean expansion of CD3
neg/CD16-or-56
pos NK cells on Clone 9.mbIL21 from
unfractionated PBMC (n=19), unfractionated PBMC followed by NK purification at day 14 of expansion (n=3), or from NK cells purified from PBMC at
day 0 prior to expansion (n=13). Mean +/2 SD is shown for each plot. All p values indicated are for t-test of fold expansion at the end of the
expansion period.
doi:10.1371/journal.pone.0030264.g003
mbIL21 Expansion of NK Cells
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days in NK cell media as described above. At the end of one week
the expanded NK cells were frozen. Matched sets of expanded and
unexpanded NK cells were thawed and assayed for telomere
length using the reference cell line CEM-1301 as previously
described [67] with minor modification. Briefly, 10
6 cells were
resuspended in hybridization buffer containing 75% deionized
formamide (Spectrum Chemicals), 20 mM Tris, pH 7.0, 1% BSA,
with or without 0.3 mg/ml telomere-specific FITC conjugated
(C3TA2)3 PNA probe (Panagene). Samples were prepared in
duplicate and subjected to heat denaturation of DNA for 15 min
at 87uC followed by hybridization for 3 h at RT. Cells were then
washed three times with 1 ml of wash buffer containing 70%
formamide, 10% 10 mM Tris, 0.1% BSA, and 0.1% Tween 20
and once with 5% dextrose containing 10 mM Hepes, 0.1% BSA,
and 0.1% Tween 20. After the last wash cells were resuspended in
PBS containing 0.1% BSA, 10 mg/ml RNAse A (Cayman
Chemical) and 0.06 mg/ml propidium iodide (BD Biosciences),
incubated 2–3 h at room temperature and analyzed on a
FACSCalibur flow cytometer (BD Biosciences). FITC-labeled
fluorescent calibration beads (Quantum
TM FITC MESF, Bangs
Laboratories) were used for daily calibration of the FACS machine.
Relative telomere length (RTL) was determined using CEM-1301
reference cells, calculated as: RTL=(MFIsample cells with probe2
MFIsample cells without probe)/(MFIreference cells with probe2MFIreference
cells without probe). The RTL of expanded NK cells was compared
directly with same-donor unexpanded cells and reported as percent
change.
Determination of cytokine secretion by NK cells
NK cells were co-cultured overnight with parental K562 at a 1:1
ratio. Supernatants were collected and concentrations of TNF-a,
IFN-c, and IL-6 were simulataneously determined using micro-
particle-based cytokine capture on Cytometric Bead Array (CBA)
kits (BD Biosciences). Concentrations were calculated from mean
fluorescent intensity based on standard curves and formulas
provided with the kit.
nCounter digital multi-plexed gene expression analysis
Gene expression in NK cells stimulated with mbIL15 or
mbIL21 was assessed using the nCounter platform (nanoString
Technologies, Inc., Seattle, WA) [68]. Purified NK cells from four
donors were stimulated for one week in parallel expansions with
either Clone 4 (mbIL15) or Clone 9.mbIL21). Total RNA was
purified from each sample and assessed for expression of 96 genes.
Gene expression was normalized to LDH (mean 6,076 copies
detected from 100 ng of loaded mRNA), and plotted as mean 6
SEM. Genes with borderline detection (#10 normalized tran-
scripts detected) were excluded from further analyses. Genes
having $2-fold difference in mean expression between mbIL21
and mbIL15 culture were then identified.
Statistics
Results are expressed as the mean 6 SD or mean 6 SEM as
indicated. Student’s t test was performed for pair-wise compari-
sons. Cytotoxicity across E:T ratios were compared between
groups using Two-way Repeated Measures ANOVA. One-way
ANOVA with Dunnett’s multiple comparisons test was applied to
telomere lengths after stimulation with Clone 4 (mbIL15) as
compared to other aAPCs. Statistical analysis was performed using
Prism 5 for Mac Os X, version 5.0c (GraphPad Software, La Jolla,
CA). P values less than 0.05 (*), less than 0.01 (**), less than 0.001
(***), or less than 0.0001 (****) were considered significant.
Results
mbIL21 supports improved proliferation of NK cells
compared to mbIL15
We developed aAPCs for expansion of antigen-specific T cells
by lentiviral transduction of the K562 cell line with CD64, CD86,
CD137L, and truncated CD19, with (Clone 9) or without (Clone
4) mbIL15 [61,69]. Based on a potential role of IL-21 in T-cell and
NK-cell maturation and proliferation, we then developed mbIL21
[61] and used Sleeping Beauty transposition to produce derivative
aAPCs bearing an IL-15:IL15Ra fusion (Clone 27), mbIL21
(Clone 9.mbIL21), or both mbIL15 and mbIL21 (Clone D2)
(Table 1). Typical transgene expression of Clone 9.mbIL21 is
shown (Figure 1A), and we confirmed stability of the transgenes
during 6 months of continuous culture (Figure 1B).
Using Clone 4, Clone 9.mbIL21, and Clone D2, we compared
the expansion of NK cells in response to recursive stimulation by
these APCs (Figure 2), normalizing the expansion to the NK cell
content of each starting PBMC product. From PBMCs of 22
donors expanded in parallel with Clone 4 and Clone 9.mbIL2, we
found that mbIL21 resulted in significantly greater fold expansion
at 3 weeks (47,967+/242,230, mean +/2 SD) than mbIL15
(825+/21108, mean +/2 SD) (Figure 3A). PBMCs from four
of these donors were also expanded with Clone D2 aAPCs
expression both of these membrane-bound cytokines, which did
not yield significantly greater expansion than mbIL21 alone
(Figure 3A).
Since expansion of NK cells on aAPC expressing IL15 had
previously been shown to be limited by telomere-induced sene-
scence, we then initiated expansion of purified NK cells from four
additional donors with Clone 4 (mbIL15) and Clone 9.mbIL21,
and continued the expansion for 6 weeks to determine whether
mbIL21-expanded NK cells would also undergo senescence. We
found that mbIL15-supported NK cells slowed in their prolifer-
ative rate at 4–6 weeks as previously reported, whereas mbIL21-
supported NK cells did not (Figure 3B).
Expansion of NK cells from PBMC induces donor-
dependent non-specific T-cell expansion
We noted that both Clone 4 and Clone 9.mbIL21 also
stimulated significant non-specific T-cell expansion when PBMC
were used as the starting product for NK-cell expansion. Among
20 NK-cell expansions with mbIL21 starting from an unfraction-
ated PBMC product, we found that with successive stimulations
during the culture period NK cells gradually became the
predominant cell type with a relative loss of T cells (Figure 3C),
as has been noted with other methods of NK-cell expansion [11].
Although NK cells rapidly increased in percentage for all donors
over the first two weeks, this differential proliferation of NK cells
tapered thereafter, resulting in a mean T-cell contamination of
21.7% (median 7.8%) by day 21. Although there was wide inter-
donor variation, it was apparent that T-cell depletion would be
required if the expanded products were to be given clinically in the
setting of allogeneic adoptive transfer.
Since the expansion of purified NK cells (Figure 3B) appeared to
be delayed during the first week compared to those expanded from
PBMC (Figure 3A), we then determined whether NK cell
expansion was affected by T-cell depletion in order to determine
when it would be best performed to produce a clinically-viable
product. Compared with NK cell proliferation in T-cell replete
cultures, T-cell depletion prior to NK cell expansion or on day 14
just prior to the third stimulation resulted in no difference in
proliferative rates.
mbIL21 Expansion of NK Cells
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results in similar expression of activating and inhibitory
receptors
Because IL-15 and IL-21 signal primarily through different
STAT family molecules (STAT5 vs. STAT3, respectively), we
questioned whether expansion with mbIL15 and mbIL21 might
result in different NK-cell phenotypes, and assessed surface
expression of the major NK-cell receptors on expanded NK cells.
Although there was variation between donors, particularly in
expression of KIR, Clone 4- and Clone 9.mbIL21-expanded NK
cells were similar in both the percentage of positive cells and the
relative receptor expression (MFI) for the receptors assessed
(Figure 4A), with a slight decrease in NKp46
pos cells and a non-
statistical trend towards increased number of CD56
negCD16
pos cells
(Figure 4B). NK cells expanded by both methods were primarily
CD16
brightCD56
pos and expressed high levels of natural cytotoxicity
receptors and KIR. When compared with freshly-isolated NK cells,
mbIL21-expanded NK cells were similar to mbIL15-expanded NK
cells in increased numbers of cells positive for KIR2DL2,3 and
NKp44, and slightly decreased in NKp30
pos cells (Figure 4B).
NK-cell expansion supported by mbIL15 or mbIL21
results in similar expression of immune-related genes
We applied the nCounter technology for multiplex measurement
of RNA [68] to accurately identify subtle changes in transcriptional
profiles induced by mbIL21 as compared to mbIL15. We used a 96-
gene panel initially developed for evaluating gene expression in T
cells propagated on K562 aAPCs, and which assesses a broad
variety of signaling, cytokine, chemokine, and cytolysis-related
genes (Table S1). We found very high correlation between NK cells
propagated with the support of mbIL15 and mbIL21 (Figure 5),
with only 9 genes showing more than 2-fold differential expression
between the two conditions. Only one of these, CD160, reached
statistical significance between donor replicates when corrected for
multiple comparisons (Figure 5, inset). Of note, the top ten genes
expressed in these cells (other than LDH) were GZMB, PRF, FOS,
CCL5, JUNB, IL2RG, IL2RB, TGFB1, IFNG, and S100A4, all
associated with increased cell proliferation, activation, or known
NK-cell effector function.
NK-cell expansion with mbIL21 results in a significant
increase in telomere length compared to mbIL15
Since expansion with mbIL15 was previously shown to be
limited by telomere shortening [70] and we had seen significantly
reduced senescence when NK cells were expanded with mbIL21,
we questioned whether the telomeres of expanded NK cells
differed depending on the cytokine support they received. To
ensure that the telomere shortening previously shown was not a
result of inadequate signaling of the mbIL15 because of lacking
higher-affinity binding provided by the sushi domain during
transpresentation by IL15Ra, we also constructed an aAPC
(Clone 27) expressing the IL15:IL15Ra fusion (IL-15 fused with a
linker to IL-15Ra). We then determined the telomere lengths of
fresh NK cells seven days after stimulation with Clone 4, Clone 27,
Clone 9, or Clone 9.mbIL21, as compared to the telomere length
of freshly-obtained unstimulated NK cells. IL-2 or mbIL15-
expanded NK cells showed a nonsignificant trend towards slightly
longer mean telomere lengths during this first week, whereas
mbIL21 caused a significant increase in the mean telomere lengths
of expanded NK cells (Figure 6A) despite having the greatest
amount of proliferation. We then assessed the telomere lengths of
21-day expanded NK cells compared to fresh NK cells. Despite a
mean 58-fold greater expansion at this timepoint mbIL21-
expanded NK cells had increased their telomere lengths by a
mean of 11.69%, where expansion with mbIL15 resulted in a
mean 11.85% decrease in telomere length (Figure 6B).
mbIL21-expanded NK cells have high cytotoxicity and
cytokine secretion and retain KIR inhibition
With high expression of granzyme B and perforin (Figure 5), we
expected NK cells expanded with mbIL21 to be cytotoxic against
tumor targets. However, others have reported that IL-21 has an
Figure 4. Phenotype of NK cells expanded on aAPCs bearing membrane-bound cytokines. NK cells purified from PBMC were stimulated
weekly with either Clone 4 (mbIL15) or Clone 9.mbIL21 for 3 weeks. Expression of NK cell receptors was determined by flow cytometry. A)
Representative dot plots of NK cells expanded from the same donor on Clone 4 (mbIL15) or Clone 9.mbIL21. B) Component subpopulations of fresh
NK cells or NK cells expanded on Clone 4 (mbIL15) or Clone 9.mbIL21 from 4 donors as determined by flow cytometry. Mean +/2 SD is shown. P
values are for 2-way repeated-measures ANOVA comparing against mbIL21-expanded NK cells with Bonferroni correction (all significant P values are
indicated).
doi:10.1371/journal.pone.0030264.g004
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expression of activating receptors [71], and the high expression of
inhibitory KIR on expanded NK cells (Figure 4) led us to question
whether they had enhanced inhibition by KIR ligands compared
to that of non-expanded NK cells. We used the 721.221 cell line,
which is HLA-negative, and two variants of this cell line
transduced to express a group C1 (HLA-C*0702) or Bw4
(B*5801) KIR ligand as previously described [58], and assessed
cytokine secretion in response to the parental K562 cell line. We
found that the cytolytic ability of the mbIL15- or mbIL21-
expanded NK cells toward the 721.21 cell line were similar and
much greater than that of freshly isolated NK cells (Figure 7A). In
contrast, mbIL21-expanded NK cells expressed significantly
higher amounts of IFN-c (mean 2629 pg/ml vs 26 pg/ml) and
TNF-a (mean 90 pg/ml vs. 2 pg/ml) than mbIL15-expanded NK
cells (Figure 7B). When cryopreserved mbIL21-expanded NK cells
were recovered overnight with IL-2, they exhibited similar
cytolysis of each of the KIR-ligand-expressing 721 targets
(Figure 7C–E) as cryopreserved unexpanded NK cells recovered
overnight with IL-2, suggesting that their responses to KIR ligands
were unaffected by expansion.
NK cells expanded with mbIL21 retain cytotoxicity against
a wide variety of tumor cell lines and participate in ADCC
We next evaluated the cytotoxicity of mbIL21-expanded NK
cells from four donors against a panel of human tumor cell lines
representing myeloid, lymphoid, sarcoma, and carcinoma tumor
types (Figure 8). In order to allow the most consistent comparisons
between multiple donors and across multiple cell targets, we
cryopreserved the NK cells after expansion. Unlike most reports of
primary NK cells which cryopreserve poorly, we found that the
expanded NK cells retained high viability 24 h after thawing with
low-dose IL-2 rescue (.90%, data not shown). We found
moderate to high cytotoxicity against all cell lines tested, with
high sensitivity of AML (Figure 8 A, B) and neuroblastoma
(Figure 8 E, F) as is commonly described.
To evaluate the interactions between NK cells and tumor
targets during the killing process, we performed video microscopy
of expanded NK cells co-cultured with calcein-labeled CHP-134
neuroblastoma cells as targets (Movie S1). The apparent contact
time between NK cells and targets ranged from 1 to 8 frames (4 to
32 minutes), and some NK cells appeared to kill several target cells
in rapid succession.
Figure 5. Gene expression in NK cells stimulated with mbIL15 or mbIL21 as assessed using the nCounter platform. Paired aliquots of
purified NK cells from 4 donors were stimulated for one week with either Clone 4 (mbIL15) or Clone 9.mbIL21. Total RNA was purified and equal
quantities hybridized for detection of expression of 96 genes. Gene expression was normalized to LDH (mean 6,076 copies detected), and the
remaining data for each gene plotted as mean +/2 SEM for each expansion condition. Genes with detection below background (set at #10 detected
copies) were excluded as not biologically significant (grey box). The ten highest-expressed genes in addition to LDH are labeled, as are genes that are
differentially expressed by .2 fold (red) or ,0.5 fold (blue) in mbIL21-expanded cells. Differentially expressed genes were replotted (inset) for
comparison, and two-tailed t-test applied.
doi:10.1371/journal.pone.0030264.g005
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bright by flow
cytometry, we also hypothesized that they would participate in
ADCC and exhibit enhanced cytotoxicity to antibody-labeled
targets. Despite already exhibiting high baseline cytotoxicity
towards Raji, the expanded NK cells showed a significant increase
in cytotoxicity with the addition of rituximab (Figure 8I).
Moreover, the ARH-77 cell line, which is reported to be
rituximab-resistant, also showed significant sensitivity to ritux-
imab-mediated ADCC (Figure 8J). Despite poor reported affinity
of human CD16 for murine IgG2a, the 14.G2a anti-GD2
monoclonal also mediated significant ADCC by expanded NK
cells when tested against GD2-expressing neuroblastoma and
melanoma cell lines (Figure 8K–L).
Discussion
Pilot studies of adoptive transfer of IL-2-activated NK cells have
demonstrated responses in a wide variety of malignancies
(reviewed in reference [72]). However, advances in adoptive
immunotherapy with NK cells have been hindered by the lack of
robust, clinically-relevant methods for NK cell expansion. There
have been important recent advances in this regard, but the
methods describing the greatest fold expansion to date have
nonetheless been limited by NK cell senescence resulting from
telomere shortening. Here we describe the introduction of a
membrane-bound chimera of IL-21 to K562-based aAPCs,
abrogating the need for clinical-grade production of cytokines
Figure 6. Change in relative telomere length of purified NK cells after expansion on aAPCs with or without membrane-bound
cytokines. NK cells were purified from normal donor buffy coats. An aliquot was viably frozen for later comparison, and the remaining cells were
stimulated with IL-2 and irradiated aAPCs bearing no cytokine (Clone 9), mbIL15 (Clone 4), mbIL21 (Clone 9.mbIL21), or IL-15 fused with a linker to
IL15Ra (Clone 27). (A) Telomere length of the NK cells was determined after 7 days by flow cytometry after hybridization with FITC-labeled PNA probe
for the TTAGGG telomeric repeat sequence. Mean fluorescence of the NK cells was normalized to the reference cell line CEM-1301, and the telomere
length of expanded NK cells was normalized to that of fresh NK cells for each individual donor. A 1-way ANOVA with Dunnett’s multiple comparisons
test was applied to compare each aAPC to Clone 4. (B) NK cells from four additional donors stimulated weekly for 21 days prior to assessing telomere
length, and again normalized to that of fresh cells from each donor. P value shown for two-tailed t-test.
doi:10.1371/journal.pone.0030264.g006
Figure 7. Direct cytotoxicity and cytokine secretion of fresh NK cells, mbIL15-expanded, and mbIL21-expanded NK cells. NK cells
were purified from four normal donor buffy coats and assessed directly, and then retested after being expanded for 21 days with Clone 9.mbIL21 and
Clone 4 (mbIL15) (with CD3 depletion on day 14). NK cells were assessed for cytotoxicity against 721.221 (A) or cytokine secretion in response to K562
(B). NK cells from another four donors were purified and cryopreserved, and expanded with Clone 9.mbIL21 and then cryopreserved. Fresh (circles)
and expanded (squares) NK cells were then thawed and activated in parallel for 24 h in 50 IU/mL IL-2, and then tested for cytotoxicity against HLA
null
721.221 targets (C), C*0702-transduced (Group C1) 721.221 targets (D), or B*5801-transduced (Group Bw4) 721.221 targets (E). All data points shown
are mean +/2 SEM of the means of four donors tested in triplicate.
doi:10.1371/journal.pone.0030264.g007
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cells with increased telomere lengths and greatly reduced
senescence.
IL-2, IL-15, and IL-21 are all members of the common c-chain
receptor family and their effects on NK cells are well-described.
IL-21 is known to signal primarily through the STAT3 component
of the JAK/STAT pathway with very little STAT5 involvement,
whereas IL-15 signals primarily through STAT5. STAT3 is
known to be an activator of human telomerase reverse
transcriptase (hTERT) [73], and NK-cell senescence from
mbIL15-mediated expansion can be restored with hTERT gene
modification [70], though the cells become cytogenetically
unstable. We found that NK cells expanded with mbIL21 have
longer telomeres than those expanded with mbIL15. NK cells
expanded with mbIL15 had shorter telomeres than those
expanded with soluble IL2 alone, but this was likely a result of
increased proliferation, not decreased hTERT activity. Increased
TERT expression may also increase survival through mechanisms
independent of telomere shortening [74]. Thus, the influence of
IL-21 and STAT3 signaling on NK cell apoptosis should be
explored. Adoptive transfer of lymphocytes with longer telomeres,
e.g. ‘‘young TIL’’, may have a significant advantage in the clinical
setting through their greater potential for in vivo expansion [75].
IL-21 has both immunosuppressive and immunostimulatory
effects on anti-tumor immunity [76]. IL-21 and STAT3 signaling
are dispensable in some murine models of immunity [77,78] and
essential in others [79]. IL-21 has a differential effect on malignant
lymphoid cell lines of B cell and T cell origin- it induces growth
stimulation in B cell lines, but in T cell lines it promotes apoptosis
through increased Bax, caspase-3, and caspase-8, but decreased
Bcl-2 expression [80]. However, the direct role of IL-21 and
STAT3 activation on NK cells is less well defined and somewhat
Figure 8. Direct and antibody-dependent cellular cytotoxicity of mbIL21 expanded NK cells toward tumor cell lines. NK cells were
expanded for 21 days from four normal donors with CD3 depletion on day 14, and then cryopreserved in aliquots. NK cells were thawed and rested
for 24 h in 50 IU/mL IL-2, and then tested for cytotoxicity against the indicated tumor cell lines using the calcein release assay. Assays were
performed in triplicate, and results are shown as mean +/2 SD for each donor against representative AML (A, B), B-cell (C, D), neuroblastoma (E, F),
colon carcinoma (G), and melanoma (H) tumor cell lines. Squares, circles, triangles, and inverted triangles correspond to the expanded NK cells from
the same four independent donors in each panel. I–L, expanded NK cells were tested for direct cytotoxicity (circles) or ADCC (squares) against B cell
tumors (I, J) using anti-CD20 antibody (rituximab), or neuroblastoma (K) and melanoma (L) using anti-GD2 antibody (14G.2a). Data shown are
mean +/2 SEM of each donor tested in triplicate (A–H) or of the means of all four donors (I–L).
doi:10.1371/journal.pone.0030264.g008
mbIL21 Expansion of NK Cells
PLoS ONE | www.plosone.org 9 January 2012 | Volume 7 | Issue 1 | e30264controversial. IL-21 promotes differentiation of cord blood
hematopoietic stem cells into NK-like lymphocytes when com-
bined with Flt3-L and stem cell factor (SCF) [81]. IL-15 and IL-21
are synergistic for cytokine secretion [50,82], cytotoxicity [50],
proliferation [27,83], and KIR expression [27], but soluble IL-21
severely blocks the IL-15-induced proliferation of murine NK cells
[50,51], in sharp contrast to our findings of enhanced proliferation
when mbIL21 was added to mbIL15. Though IL-21 has been
reported to downregulate NKG2D in NK cells [71], we found no
difference in NKG2D expression between NK cells expanded with
mbIL15 and mbIL21 in our system.
We also found that expression of CD160 mRNA transcripts was
increased in mbIL21-expanded NK cells compared to those
expanded with mbIL15, and confirmed increased expression of
CD160 by flow cytometry (not shown). The transmembrane form
of CD160 has been identified as a receptor selectively expressed on
activated NK cells [84,85]. K562 may express small amounts
HLA-C, the physiologic ligand for CD160, and engagement of
CD160 results in distinct cytokine secretion profile of IL-6, IFN-c,
and TNF-a [86]. Thus, increased CD160 expression in mbIL21-
expanded NK cells may effect proliferation, cytokine profiles, or
anti-tumor activity.
NK cells play a crucial role in antibody immunotherapy through
ADCC, but expansion of NK cells has been sufficiently problematic
in the past that others have proposed adoptive immunotherapy with
expanded cd T cells [87] or CD16 gene-modified [88] T cells as
alternative approaches to enhancing ADCC of anti-cancer
antibodies. IL-21 can enhance cytotoxicity to antibody-coated
tumor targets [89], consistent with our finding of high expression of
CD16 and functional ADCC in mbIL21-expanded NK cells. The
relatively minor increase in cytotoxicity provided by ADCC with
anti-GD2 mAb may be a result of the low affinity of this murine
isotypeforhumanCD16,the highbaselinecytotoxicityofexpanded
NK cells for these targets, or that tumor cells may acquire resistance
to ADCC through expression of their own FcRcIIb [90].
Enhancing ADCC by adoptive transfer of such cells may overcome
some mechanisms of resistance, as we demonstrated for rituximab.
Techniques for enhancing antibody-binding to CD16, the low-
affinity Fcc receptor, will further improve this approach [91].
In addition to wide variation in NK cell content of peripheral
blood, there is wide variation in the proportion that are CD56
hi,
accounting for 3.5–37.5% of total NK cells [5]. In peripheral blood,
CD56
hiCD16
neg NK cells are understood to represent an immature
stage of NK cell development characterized by increased prolifer-
ative potential [92] and longer telomeres [93], and these
populations are differentially effected by IL15 and IL21 [27].
However, this population persists in both mbIL15 and mbIL21-
expanded cultures, and despite the fact that mbIL21-epxanded cells
have increased proliferation and longer telomeres, the proportion
of CD56
hiCD16
pos is not different between the two membrane-
bound cytokines. In addition, others have demonstrated that
CD56
dimCD16
pos NK cells do not have significant anti-tumor
cytotoxicity, which we find is not true of ex vivo expanded NK cells.
The critical ligandsprovided byK562forNKcellexpansion have
not been clearly defined. In ex vivo NK cell expansion driven by
allogeneic feeder cells, proliferation is enhanced in cells expressing
KIR for which the self-HLA ligand is missing [94]. However, HLA
engagement by CD160 promotes optimal cytokine release by NK
cells [86]. Since K562 has only very low expression of HLA-Cw3
[95], this may explain the slight repertoire bias for KIR2DL2,3-
expressing cells when expanded on K562 aAPCs. This raises the
possibility that intentional skewing of the KIR repertoire during
expansion could be accomplished by additional engineering of the
aAPCs to express desired HLA haplotypes for KIR-mediated
inhibition and/or licensing. In addition, high-dose IL-2 has been
shown to preferentially expand KIR
neg NK cells. In contrast,
expansion with K562 aAPCs results in NK cells with KIR diversity
and high KIR expression. However, despite high KIR expression,
we saw no difference in responses to KIR-ligand-engineered targets
as compared to unexpanded NK cells. This data, along with our
data regarding CD56
hiCD16
pos subsets, suggests that the immuno-
phenotype of ex vivo expanded NK cells may not be predictive of
functionwhencomparedtoknownperipheralbloodsubpopulations.
We were able to expand our NK cells with relatively low concen-
trations of IL-2 and observe high viability and sustained function
after cryopreservation. Such properties may enable production of
qualified cryopreserved lots for repeated doses in adoptive
immunotherapy, and may allow reduced in vivo IL-2 support.
NK cells have demonstrated anti-cancer effect in clinical trials.
However, their widespread use is hampered by the ability to
generate large numbers of these cells ex vivo. Currently, most
investigators rely on leukapheresis, commercially-available para-
magnetic beads, and clinical large-scale magnetic separation
devices to generate NK-cell products, a process that is expensive
and results in cells with either sub-optimal purity (CD3-depletion
alone) or potency (CD3 depletion and CD56 selection). Because
most methods of NK-cell expansion also result in some degree of
non-specific T-cell expansion, and contaminating T cells in the
clinical NK-cell product should be avoided because of the
attendant risk of GvHD (particularly in the setting of haploiden-
tical donors), we employed T-cell depletion at various stages of the
expansion process. To avoid the need for large-scale CD3-
depletion of the final product (which would be very costly at higher
cell doses [96]), we first attempted selection of NK cells prior to
expansion, similar to that described by Berg [41], and found no
significant effect on the proliferation of the NK cells. Early timing
of T-cell depletion will enable pure NK cell products to be
propagated with aAPCs to clinically-appealing numbers from a
single venipuncture sample, circumventing the need for apheresis
or large-scale depletion. To achieve a GMP-compliant system of
lymphocyte expansion that minimizes reliance on external sources
of GMP-grade cytokines, our group has focused on generating
aAPCs with membrane-bound cytokines [60,61,97,98]. The
method we used herein requires only low concentrations of IL-2
(50 IU/mL). In addition, we have achieved the high expansion
rate described without the use of specialized culture media
required by other systems. All of these features should reduce the
costs associated with NK cell adoptive immunotherapy.
Adoptive transfer of NK cells after lymphodepleting chemo-
therapy has shown promise in a variety of cancer settings, but the
greatest potential may be realized in the post-transplant setting, as
early and vigorous NK cell reconstitution may reduce GvHD,
reduce infectious complications, and increase anti-cancer activity
in the MRD setting. Though the lack of adequate numbers of NK
cells for adoptive immunotherapy is widely viewed as a hindrance
to advancing the field, there is still much controversy regarding
expansion methods and whether in vitro or in vivo expansion is
superior [99,100]. The increased expansion potential afforded by
mbIL21 should eliminate the need for donor apheresis, enable
cryopreservation and single lot-release testing of multiple infusion
aliquots for repeated dosing, and provide sufficient cells from a
single venipuncture to achieve total cell doses in excess of 10
10/kg,
enabling clinical trials that address these questions.
Supporting Information
Table S1 Transcription of a selected set of immune-
related genes was performed using the nanoString
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The common gene name, the accession number and region for the
sequence against which the target gene probe was designed, and
the unique capture/detection sequences for each gene are listed as
indicated.
(XLS)
Movie S1 Video fluorescent microscopy of NK cell
lysis of neuroblastoma targets. CHP134 neuroblastoma
targets were loaded with calcein dye as described. NK cells were
added to target cells at a 5:1 E:T ratio, and fluorescent and
brightfield images were acquired at 4-minute intervals using
the Nikon BioStation. Sudden loss of fluorescence indicates
a loss of cell membrane integrity associated with perforin release
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